Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Free Report)’s share price was down 1.7% during trading on Wednesday . The stock traded as low as $11.30 and last traded at $11.30. Approximately 606 shares were traded during trading, a decline of 30% from the average daily volume of 865 shares. The stock had previously closed at $11.50.
Finch Therapeutics Group Trading Down 1.7 %
The company has a market capitalization of $18.19 million, a P/E ratio of -1.28 and a beta of 1.31. The company’s 50 day moving average is $11.29 and its 200-day moving average is $10.25.
Finch Therapeutics Group Company Profile
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
See Also
- Five stocks we like better than Finch Therapeutics Group
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Options Trading – Understanding Strike Price
- 3 Steel Stocks Soaring After Tariff Announcements
- Most Volatile Stocks, What Investors Need to Know
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.